Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
  • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
  • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
  • C07H19/16—Purine radicals
  • C07H19/167—Purine radicals with ribosyl as the saccharide radical
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
  • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
  • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
  • C07H19/16—Purine radicals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
  • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
  • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
  • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
  • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H1/00—Processes for the preparation of sugar derivatives

Definitions

• the present invention relates to novel adenosine derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine.
• R 2 represents C ⁇ - 3 alkyl, halogen or hydrogen
• R 3 represents a fluorinated straight or branched alkyl group of 1-6 carbon atoms
• R 1 represents a group selected from
• cycloalkyl including bridged cycloalkyl, said cycloalkyl group being optionally substituted by one or more substituents selected from OH, halogen, -(C ⁇ ) alkoxy, wherein (alk) represents C ⁇ 3 alkylene and n represents 0 or 1.
• Ci 12 alkyl optionally including one or more O,
• B represents a 5 or 6 membered heterocyclic aromatic group containing 1 or more O, N or S atoms wherein the bicyclic ring is attached to the nitrogen atom of formula (I) via a ring atom of ring A and ring B is optionally substituted -CO - (C., 3 alkyl)
• a phenyl group substituted by a 5 or 6 membered heterocyclic aromatic group said heterocyclic aromatic group optionally being substituted by C ⁇ 3 alkyl or NR c R d R c and R may each independently represent hydrogen, or C ⁇ alkyl or when part of a group NR c R d , R c and R d together with the nitrogen atom may form a 5 or 6 membered heterocyclic ring optionally containing other heteroatoms, which heterocyclic ring may optionally be substituted further by one or more C 1 3 alkyl groups
• R e represents C 3 alkyl
• the adenosine A1 agonists of the general formula (I) above exhibit greater activity at the adenosine A1 receptor than the other adenosine receptor subtypes, particularly A3
• alkyl means a straight or branched ?? alkyl group
• suitable alkyl groups within R 1 and R 2 include methyl, ethyl, n- propyl, i-propyl, n-butyl, s-butyl, t-butyl and 2,2-d ⁇ methylpropy!
• alkylene means a straight or branched chain alkylene group containing 1 to 6 carbon atoms e g methylene
• C 2 . 6 alkenyl means a straight or branched chain alkenyl group containing 2 to 6 carbon atoms Allyl represents an example of a suitable C 2 . 6 alkenyl group
• halogen means fluorine, chlorine, bromine or iodine
• aliphatic heterocyclic group is meant a cyclic group of 4-6 carbon atoms wherein one or more of the carbon atoms is/are replaced by heteroatoms independently selected from nitrogen, oxygen or sulfur. This group may optionally be substituted as defined hereinabove.
• heterocyclic aromatic group refers to an aromatic mono or bicyclic ring system comprising from 5 to 10 carbon atoms wherein one or more of the carbon atoms is/are replaced by heteroatoms independently selected from nitrogen, oxygen and sulfur, which ring system may optionally be substituted as defined hereinabove.
• Pharmaceutically acceptable salts of the compounds of formula (I) include those derived from pharmaceutically acceptable inorganic and organic acids.
• suitable acids include hydrochloric, hydrobromic, sulphuric, nitric, perchloric, fumaric, maleic, phosphoric, glycollic, lactic, salicylic, succinic, toluene-p-sulphonic, tartaric, acetic, citric, methanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic and benzenesulfonic acids.
• a particularly suitable pharmaceutically acceptable salt of the compounds of formula (I) is the hydrochloride salt.
• Other acids such as oxalic, while not in themselves pharmaceutically acceptable, may be useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
• the solvates may be, for example, hydrates.
• R 3 preferably represents a C ⁇ fluoroalkyl group especially a fluoromethyl group. More preferably R 3 represents a trifiuromethyl group.
• R 2 preferably represents hydrogen, methyl or halogen, more preferably hydrogen, methyl or chlorine.
• R may represent (alk) n -C 3 _ 6 -cycloalkyl wherein n is 0 or 1 and the said cycloalkyl is either substituted by at least one substituent selected from halogen, particularly fluorine, and OH or is unsubstituted.
• n represents zero. More preferably, the cycloalkyl group is monosubstituted by
• the alphatic heterocyclic group is unsubstituted or when the substituent is -CO 2 (C 1 4 )alkyl the heteroatom is nitrogen and the substituent is attached directly to said ring nitrogen atom
• heterocyclic ring is 5 or 6 membered and more preferably contains only one O, N or S heteroatom
• the alkyl group conveniently may be unsubstituted or substituted by at least one OH group
• R 1 may represent a phenyl group which is substituted by one or more substituents selected from OH and halogen
• substituents selected from OH and halogen
• the phenyl is disubstituted in the 2,4 positions
• both substituents are halogen more particularly, fluorine and chlorine
• a particularly preferred combination is 2-fluoro and 4-chloro
• Compounds according to the invention have applicability as inhibitors of lipolysis i.e. they decrease plasma free fatty acid concentrations.
• the compounds may thus be used in the treatment of hypertipidaemias.
• the compounds have the ability to lower elevated blood glucose, insulin and ketone body levels and therefore may be of value in the therapy of diabetes.
• anti-lipolytic agents have hypolipidaemic and hypofibrinogenaemic activity, the compounds may also show anti-atherosclerotic activity.
• the anti-lipolytic activity of compounds of the invention has been demonstrated by their ability to lower the concentration of non-esterified fatty acids (NEFA) in starved rats dosed orally according to the method described by P. Strong et al. in Clinical Science (1993), 84, 663-669.
• the compounds of the invention may independently affect cardiac function by reducing heart rate and conduction.
• the compounds may thus be used in the therapy of a number of cardiovascular disorders, for example cardiac arrythmias, particularly following myocardial infarction, and angina.
• the compounds of the invention are useful as cardioprotective agents, having applicability in the treatment of ischaemic heart disease.
• ischaemic heart disease includes damage associated with both myocardial ischaemia and reperfusion, for example, associated with coronary artery bypass grafting (CABG), percutaneous translumenal coronary angioplasty (PTCA), cardioplegia, acute myocardial infarction, thrombolysis, stable and unstable angina and cardiac surgery including in particular cardiac transplantation.
• the compounds of the invention additionally are useful for treating ischaemic damage to other organs.
• the compounds of the invention may also be valuable in the treatment of other disorders arising as a result of widespread atheromatous disease, for example, peripheral vascular disease (PVD) and stroke.
• PVD peripheral vascular disease
• the compounds may also inhibit renin release and thus be of use in the therapy of hypertension and heart failure.
• the compounds may also be useful as CNS agents (e.g. as hypnotics, sedatives, analgestics and/or anti-convulsants particularly finding use in the treatment of epilepsy).
• the compounds of the invention may find use in the treatment of sleep apnoea.
• the compound of formula (I) and pharmaceutically acceptable acid addition salts thereof are useful as analgesics. They are therefore useful in treating or preventing pain. They may be used to improve the condition of a host, typically of a human being, suffering from pain They may be employed to alleviate pain in a host
• the compound of formula (I) and its pharmaceutically acceptable acid addition salts may be used as a preemptive analgesic to treat acute pain such as musculoskeletal pain, post operative pain and surgical pain, chronic pain such as chronic inflammatory pain (e g rheumatoid arthritis and osteoarthritis), neuropathic pain (e g post herpetic neuralgia, diabetic neuropathies associated with diabeties, t ⁇ geminal neuralgia, pain associated with functional bowel disorders, e g irritable bowel syndrome, non cardiac chest pain and sympathetically maintained pain) and pain associated with cancer and fibromyalgia
• the compound of formula (I) may also be used in the treatment or prevention of pain associated with migraine
• the invention provides a compound of formula (I) or a physiologically acceptable salt or solvate thereof for use in therapy, and in particular in the treatment of human or animal subjects suffering from a condition in which there is an advantage in decreasing plasma free fatty acid concentration, or reducing heart rate and conduction, or whereby the therapy involves the treatment of ischaemic heart disease, peripheral vascular disease or stroke or which subject is suffering from a CNS disorder, sleep apnoea or pain
• the invention provides a method of treatment of a human or animal subject suffering from a condition in which there is an advantage in decreasing plasma free fatty acid concentration, or reducing heart rate and conduction, or which subject is suffering from or susceptible to ischaemic heart disease, peripheral vascular disease or stroke, or which subject is suffering a CNS disorder or suffering from sleep apnoea or suffering pain, which method comprises administering to the subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof
• reference to treatment includes acute treatment or prophylaxis as well as the alleviation of established symptoms
• the invention provides a pharmaceutical composition
• a pharmaceutical composition comprising at least one compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof in association with a pharmaceutical carrier and/or excipient
• the invention provides a pharmaceutical composition
• a pharmaceutical composition comprising, as active ingredient, at least one compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof in association with a pharmaceutical carrier and/or excipient for use in therapy, and in particular in the treatment of human or animal subjects suffering from a condition in which there is an advantage in decreasing plasma free fatty acid concentration, or reducing heart rate and conduction, or which subject is suffering from or susceptible to ischaemic heart disease, peripheral vascular disease or stroke, or which subject is suffering from a CNS disorder, sleep apnoea or pain
• a process of preparing a pharmaceutical composition comprises mixing at least one compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, together with a pharmaceutically acceptable carrier and/or excipient
• compositions according to the invention may be formulated for topical, oral, buccal, parenteral or rectal administration or in a form suitable for administration by inhalation or insufflation Oral administration is preferred
• the compositions may be adapted for sustained release
• the pharmaceutical composition may be given in the form of a transdermal patch.
• Tablets and capsules for oral administration may contain conventional excipients such as binding agents, for example mucilage of starch or polyvinylpyrrolidone; fillers, for example, lactose, microcrystalline cellulose or maize-starch; lubricants, for example, magnesium stearate or stea c acid; disintegrants, for example, potato starch, croscarmellose sodium or sodium starch glycollate; or wetting agents such as sodium lauryl sulphate.
• binding agents for example mucilage of starch or polyvinylpyrrolidone
• fillers for example, lactose, microcrystalline cellulose or maize-starch
• lubricants for example, magnesium stearate or stea c acid
• disintegrants for example, potato starch, croscarmellose sodium or sodium starch glycollate
• wetting agents such as sodium lauryl sulphate.
• the tablets may be coated according to methods well known in the art.
• Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use.
• Such liquid preparations may contain conventional additives such as suspending agents, for example, sorbitol syrup, methyl cellulose, or carboxymethyl cellulose; emulsifying agents, for example, sorbitan mono-oleate; non-aqueous vehicles (which may include edible oils), for example, propylene glycol or ethyl alcohol; and preservatives, for example, methyl or propyl p--hydroxybenzoates or sorbic acid.
• the preparations may also contain buffer salts, flavouring, colouring and sweetening agents (e.g. mannitol) as appropriate.
• compositions may take the form of tablets or lozenges formulated in conventional manner.
• the compounds of formula (I) may be formulated for parenteral administration by bolus injection or continuous infusion and may be presented in unit dose form in ampoules, or in multi-dose containers with an added preservative.
• the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents.
• the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.
• the compounds of formula (I) may also be formulated as suppositories, e.g. containing conventional suppository bases such as cocoa butter or other glyce des.
• a proposed dose of the compounds of the invention for administration to man is 1 mg to 2g, preferably 1mg to 100mg, of the active ingredient per unit dose which could be administered, for example, 1 to 4 times per day. It will be appreciated that it may be necessary to make routine variations to the dosage, depending on the age and condition of the patient. The dosage will also depend on the route of administration.
• the invention also provides for the use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament for the treatment of human or animal subjects suffering from a condition in which there is an advantage in decreasing plasma free fatty acid concentration, or reducing heart rate and conduction, or which subject is suffering from or susceptible to ischaemic heart disease, peripheral vascular disease (PVD) or stroke, or which patient is suffering from a CNS disorder, sleep apnoea or pain.
• a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament for the treatment of human or animal subjects suffering from a condition in which there is an advantage in decreasing plasma free fatty acid concentration, or reducing heart rate and conduction, or which subject is suffering from or susceptible to ischaemic heart disease, peripheral vascular disease (PVD) or stroke, or which patient is suffering from a CNS disorder, sleep apnoea or pain.
• PVD peripheral vascular disease
• the compounds of formula (I) and physiologically acceptable salts or solvates thereof may be prepared by the processes described hereinafter, said processes constituting a further aspect of the invention.
• the groups R 1 , R 2 and R 3 are as defined for compounds of formula (I) unless otherwise stated.
• a compound of formula (I) may be prepared by reacting a compound of formula (II).
• L represents a leaving group such as a halogen atom (e.g. a chlorine atom) and P 1 and P 2 represent hydrogen or a suitable protecting group (e.g. acetyl) with a compound of formula Rl NH 2 or a salt thereof, under basic conditions.
• a leaving group such as a halogen atom (e.g. a chlorine atom)
• P 1 and P 2 represent hydrogen or a suitable protecting group (e.g. acetyl) with a compound of formula Rl NH 2 or a salt thereof, under basic conditions.
• Compounds of formula (II) may be used to produce compounds of formula (I) directly by reaction with the group R 1 NH 2 either in the absence or presence of a solvent such as an alcohol (e.g. a lower alkanol such as isopropanol, t-butanol or 3-pentanol), an ether (e.g. tetrahydrofuran or dioxan), a substituted amide (e.g. dimethylformamide), a halogenated hydrocarbon (e.g. chloroform) or acetonitrile, preferably at an elevated temperature (e.g.
• a solvent such as an alcohol (e.g. a lower alkanol such as isopropanol, t-butanol or 3-pentanol), an ether (e.g. tetrahydrofuran or dioxan), a substituted amide (e.g. dimethylformamide), a halogenated hydrocarbon (e.g. chloroform
• a suitable acid scavanger for example, inorganic bases such as sodium or potassium carbonate, or organic bases such as triethylamine, diisopropylethylamine or pyridine.
• This reaction may be preceded or followed where appropriate by in situ removal of the P 1 and P 2 protecting groups.
• P 1 and P 2 represent acetyl
• this may be effected with an amine such as ammonia or tert butylamine in a solvent such as methanol at a convenient temperature.
• P ⁇ OP' wherein P 3 represents a suitable protecting group for example C ⁇ alkyl or acetyl, and P 1 , P 2 and R 3 are as defined above, with a compound of formula (IV)
• the reaction is conveniently carried out in a suitable solvent, such as acetonitrile in the presence of a silylating agent such as trimethylsiiyl trifluoromethane sulfonate and a base such as diazabicyclo [5.4.0]undec-7-ene (DBU).
• a silylating agent such as trimethylsiiyl trifluoromethane sulfonate and a base such as diazabicyclo [5.4.0]undec-7-ene (DBU).
• DBU diazabicyclo [5.4.0]undec-7-ene
• the compound of formula (IV) may first be silylated with a suitable silylating agent, for example, hexamethyldisilazane reaction of the silylated intermediate with a compound of formula (III) and followed by a suitable Lewis acid, e.g. trimethylsiiyl trifluoromethanesulfonate in a suitable solvent such as aceton
• Compounds of formula (III) may be prepared from alternative protected compounds by replacement of the alternate protecting groups with P 1 and P 2 ; for example when P 1 and P 2 represent acetyl, compounds of formula (III) may be prepared from compounds of formula (V) wherein P 4 and P 5 represent C 1 . 3 alkyl and P3 is as defined above, by acid catalysed removal of the aikylidine protecting group, e.g. with hydrogen chloride in methanol, followed by in situ acylation for example with acetic anhydride in the presence of a base such as pyridine, in a solvent such as dichloromethane.
• aikylidine protecting group e.g. with hydrogen chloride in methanol
• in situ acylation for example with acetic anhydride in the presence of a base such as pyridine, in a solvent such as dichloromethane.
• Compound (VII) maybe treated with a suitable brominating agent, e.g. dibromomethylhydrantoin. and a pyridine/hydrogen fluoride complex in a suitable solvent such as dichloromethane according to the method of Hiyoma T. et. al., Tetrahedron Letters 1992, 4173-4176 to produce the compound of formula (V).
• a suitable brominating agent e.g. dibromomethylhydrantoin.
• a pyridine/hydrogen fluoride complex in a suitable solvent such as dichloromethane according to the method of Hiyoma T. et. al., Tetrahedron Letters 1992, 4173-4176 to produce the compound of formula (V).
• compounds of formula (I) or (II) may also be prepared from compounds wherein alkylidene groups defined by P 4 and P 5 replace P 1 and P 2 .
• This reaction represents an exchange of one protecting group for another and such reactions will be apparent to a person skilled in the art.
• a further process (B) comprises converting a compound of formula (I) into a different compound of formula (I) by modifying the R1 , R2 or R3 group therein.
• chlorination may conveniently be effected by treating (X) with phosphorus oxychloride in the presence of an organic base such as 4-dimethylaminopyridine and in a suitable solvent such as acetonitrile at an elevated temperature (e.g. up to the reflux temperature of the solvent).
• organic base such as 4-dimethylaminopyridine
• suitable solvent such as acetonitrile
• Compounds of formula (XIII) may be prepared from compounds of formula (XIV) by reaction with methane sulfonyl chloride in the presence of a suitable base such as triethylamine, diisopropylethylamine or pyridine in a suitable solvent such as dichloromethane.
• a suitable base such as triethylamine, diisopropylethylamine or pyridine
• a suitable solvent such as dichloromethane.
• R1 or R 2 or R 3 may be converted into a different R1 , or R2 or R3 grouping as an intermediate step in the overall synthesis of compounds of the invention whereas process (B) hereinabove merely describes interconversion as a final step process.
• P 1 and P 2 are suitable protecting groups as defined above and P 6 also represents a suitable protecting group.
• R 2 represents Cl
• P 1 , P 2 and P 6 all represent benzoyl (this is a known compound).
• Compounds of formula (XV) may be used to produce compounds of formula (I) by reaction with the group R 1 NH 2 either in the absence or presence of a solvent such as an alcohol (e.g. a lower alkanol such as isopropanol, t-butanol or 3- pentanol), an ether (e.g. tetrahydrofuran or dioxan), a substituted amide (e.g. dimethylformamide), a halogenated hydrocarbon (e.g. chloroform) or acetonitrile, preferably at an elevated temperature (e.g.
• a solvent such as an alcohol (e.g. a lower alkanol such as isopropanol, t-butanol or 3- pentanol), an ether (e.g. tetrahydrofuran or dioxan), a substituted amide (e.g. dimethylformamide), a halogenated hydrocarbon (e.g. chloroform)
• a suitable acid scavanger for example, inorganic bases such as sodium or potassium carbonate, or organic bases such as triethylamine, diisopropylethylamine or pyridine.
• This reaction may be preceded or followed where appropriate by in situ removal of the P 1 , P 2 and P 6 protecting groups.
• P 1 , P 2 and P 6 represent benzoyl
• this may be effected with a carbonate such as potassium carbonate in a solvent such as methanol to form a compound of formula (XVI).
• the R 3 group may then be introduced into the compound in methods apparent to those skilled in the art followed by deprotection of the compound as described in Process A above
• Specific optical isomers of a compound of formula (I) may be obtained by conventional methods for example, by synthesis from an appropriate asymmetric starting material using any of the processes described herein, or where appropriate by separation of a mixture of isomers of a compound of formula (I) by conventional means e g by fractional crystallisation or chromatography
• the compound of formula (I) obtained may be in the form of a salt, conveniently into the form of a pharmaceutically acceptable salt Where desired, such salts may be converted into the corresponding free bases using conventional methods
• compositions of formula (I) may be prepared by reacting a compound of formula (I) with an appropriate acid in the presence of a suitable solvent such as acetonitrile, acetone, chloroform, ethyl acetate or an alcohol (e g methanol, ethanol or isopropanol)
• a suitable solvent such as acetonitrile, acetone, chloroform, ethyl acetate or an alcohol (e g methanol, ethanol or isopropanol)
• Pharmaceutically acceptable base addition salts may be obtained in an analogous manner by treating a solution of a compound of formula (I) with a suitable base
• Pharmaceutically acceptable salts may also be prepared from other salts, including other pharmaceutically acceptable salts of the compounds of formula (I), using conventional methods
• Automated preparative high performance liquid chromatography was carried out using a Supelco ABZ+ 5 ⁇ m 100mmx22mm i d column eluted with a mixture of solvents consisting of i) 0.1% formic acid in water and ii) 0.05% formic acid in acetonitrile, the eluant being expressed as the percentage of ii) in the solvent mixture, at a flow rate of 4ml per minute. Unless otherwise stated the eluent was used as a gradient of 0-95 % (ii) over 20 minutes.
• This system used an ABZ+PLUS, 3.3cm x 4.6mm i.d. column, eluting with solvents: A - 0.1%v/v formic acid + 0.077%w/v ammonium acetate in water; and B - 95:5 acetonitrile:water + 0.05%v/v formic acid, at a flow rate of 1 ml per minute.
• the following gradient protocol was used: 100% A for 0.7 mins; A+B mixtures, gradient profile 0 - 100% B over 3.5mins; hold at 100% B for 3.5mins; return to 100% A over 0.3mins.
• the system used a micromass 'platform' spectrometer, with electrospray ionisation mode, positive and negative ion switching, mass range 80-1000 a.m.u.
• the analytical HPLC system used an inertsil ODS2 150mm x 4.6mm i.d. column, eluting with solvents: A - 0.1%v/v phosphoric acid in water and B - 95:5 acetonithle:water + 0.1%v/v phosphoric acid.
• the following gradient protocol was used with a flow rate of 1.0 mL/min: 100% A for 2 min; A+B mixtures, gradient profile 0 - 100% B over 40min; hold at 100% B for 10min.
• Acetic acid 4R-acetoxy- 5R-methoxy-2R-trifluoromethoxymethyl-tetrahydro-furan-3R-yl ester 0.566g
• 1 ,8-diazabicycloundec-7-ene (0.48ml)
• trimethylsiiyl trifiuoromethanesulfonate (1.03ml) were added, and the mixture stirred at 22°C for 10 min then heated under reflux under nitrogen for 2h.
• Further trimethylsiiyl trifiuoromethanesulfonate (0.7ml) was added and the solution heated under reflux under nitrogen for a further 1.5h.
• Acetic acid 4R-acetoxy-2R-(6-chloro-purin-9-yl)-5R-trifluoromethoxymethyl- tetrahydro-furan-3R-yl ester (53mg) in isopropanol (5ml) was treated with (2- amino-ethanesulfonic acid methylamide) (85mg) and di-isopropylethylamine (0.21 1ml) and heated in a reactivial at 80°C for 65h. After cooling, the solvent was removed under a stream of nitrogen, and saturated methanolic ammonia added.
• Example 18 4-[9-(3R,4S-Dihydroxy-5R-thfluoromethoxymethyl-tetrahydro- furan-2R-yl)-9H-purin-6-ylamino]-pipehdine-1 -carboxylic acid ethyl ester Prepared from Intermediate 5 Mass spectrum m/z 491 (MH + ) Nmr ⁇ (CDCI 3 ) 8.25 (1 Hs, CH[heterocyclic]), 8.15(1 Hs,CH[heterocyclic]), 6.05(1 Hd, CH), 4.7 (1 Hm, CH), 4.0-4.5 (9Hm, 5xCH + 2xCH 2 ), 3.1 (2H brt, CH 2 ), 2.08 (2H brd, 2xCH), 1.55 (2H brq, 2xCH), and 1.28 (3Ht, CH 3 )
• Acetic acid 4R-acetoxy-2R-(6-chloropurin-9-yl)-5R-thfluoromethoxymethyl- tetrahydro-furan-3R-yl ester (0.16g), 2-chloro-4-fluoroaniline (0.26ml), palladium acetate (8mg), R-BINAP (R-(+)-2,2'-Bis(diphenylphosphino)-1 ,1 '-binaphthyl) (33mg) and cesium carbonate (0.16g) in 1.2ml of toluene were heated in a reactivial at 85-91 °C for 16h.
• CRE cyclic AMP response element
• HYG hygromycin resistance
• SPAP secreted placental alkaline phosphatase reporter gene elements, which upon stimulation of cAMP levels produced SPAP.
• a cell line was used, which was stably transfected with either the human adenosine A1 receptor or the human adenosine A3 receptor in addition to the above elements. Cells were plated out in 96-well plates in culture medium and incubated at 37°C for 1 hour.
• agonists were added to the appropriate wells at a concentration range of approximately 10 ⁇ 10 - 10 "5 M. 15Min later, cAMP levels were stimulated by addition of a maximal concentration of forskolin. All cells were then incubated for a further 5 hours at 37°C, and cooled to room temperature, after which a substrate for the phosphatase (para- nitrophenol phosphate, pNPP), which is converted by SPAP to a coloured reagent) was then added and the 96-well plates were read in a plate reader. From these readings, the concentration-dependence of the inhibition by the agonist for forskolin-stimulated SPAP production can be calculated.
• pNPP para- nitrophenol phosphate
• NECA N-ethylcarboxamidoadenosine

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmacology & Pharmacy (AREA)
• Molecular Biology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Genetics & Genomics (AREA)
• Biotechnology (AREA)
• Biochemistry (AREA)
• Cardiology (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Heart & Thoracic Surgery (AREA)
• Neurosurgery (AREA)
• Diabetes (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Pain & Pain Management (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Saccharide Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (19)

Applications Claiming Priority (2)

Publications (2)

Family

ID=10821742

Family Applications (1)

Country Status (24)

Cited By (46)

Families Citing this family (16)

Family Cites Families (6)

• 1997
  • 1997-11-08 GB GBGB9723566.7A patent/GB9723566D0/en not_active Ceased
• 1998
  • 1998-11-06 EE EEP200000284A patent/EE200000284A/xx unknown
  • 1998-11-06 PL PL98341091A patent/PL341091A1/xx unknown
  • 1998-11-06 JP JP2000520458A patent/JP2001522858A/ja active Pending
  • 1998-11-06 HR HR20000276A patent/HRP20000276A2/hr not_active Application Discontinuation
  • 1998-11-06 DE DE69815378T patent/DE69815378T2/de not_active Expired - Fee Related
  • 1998-11-06 SK SK671-2000A patent/SK6712000A3/sk unknown
  • 1998-11-06 US US09/530,574 patent/US6407076B1/en not_active Expired - Fee Related
  • 1998-11-06 EA EA200000393A patent/EA200000393A1/ru unknown
  • 1998-11-06 AT AT98955538T patent/ATE242259T1/de not_active IP Right Cessation
  • 1998-11-06 BR BR9813973-8A patent/BR9813973A/pt not_active Application Discontinuation
  • 1998-11-06 EP EP98955538A patent/EP1027363B1/en not_active Expired - Lifetime
  • 1998-11-06 WO PCT/EP1998/007022 patent/WO1999024450A2/en not_active Ceased
  • 1998-11-06 CA CA002309199A patent/CA2309199A1/en not_active Abandoned
  • 1998-11-06 TR TR2000/02157T patent/TR200002157T2/xx unknown
  • 1998-11-06 HU HU0004106A patent/HUP0004106A2/hu unknown
  • 1998-11-06 CN CN98812978A patent/CN1285842A/zh active Pending
  • 1998-11-06 ES ES98955538T patent/ES2201552T3/es not_active Expired - Lifetime
  • 1998-11-06 AP APAP/P/2000/001803A patent/AP2000001803A0/en unknown
  • 1998-11-06 AU AU12327/99A patent/AU1232799A/en not_active Abandoned
  • 1998-11-06 IL IL13596598A patent/IL135965A0/xx unknown
  • 1998-11-06 KR KR1020007004974A patent/KR20010031883A/ko not_active Withdrawn
• 2000
  • 2000-05-03 IS IS5478A patent/IS5478A/is unknown
  • 2000-05-05 NO NO20002360A patent/NO20002360L/no not_active Application Discontinuation

Also Published As

Similar Documents

Legal Events